Dipyridamole, a vasodilator and antiplatelet drug, has been proposed as a possible COVID-19 therapeutic.
Mechanism of potential benefit
See the research overview by Yogendra Kanthi, Jason S. Knight, et. al: "New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm"
Clinical trials
A list of clinical trials of dipyridamole for COVID-19:
- Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19 (DICER). Intervention: Dipyridamole 100mg po 4 times a day
- Aggrenox To Treat Acute Covid-19 (ATTAC-19) Intervention: Dipyridamole ER 200mg/ Aspirin 25mg bid for 2 weeks.
- Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19 (TOLD). Intervention: Dipyridamole 100mg 3 times a day for 7 days